Stockscreener 앱 받기
3.84
2.40%
0.09
전일 마감가:
$3.75
열려 있는:
$3.65
하루 거래량:
21,644
Relative Volume:
0.71
시가총액:
$3.51M
수익:
$61,000
순이익/손실:
$-5.46M
주가수익비율:
-0.5872
EPS:
-6.54
순현금흐름:
$-6.76M
1주 성능:
+0.00%
1개월 성능:
+4.90%
6개월 성능:
-3.27%
1년 성능:
-44.19%
1일 변동 폭
$3.65
$3.88
1주일 범위
$3.59
$3.95
52주 변동 폭
$3.03
$14.80
타이탄 파마슈티컬스 Stock (TTNP) Company Profile
명칭
Titan Pharmaceuticals Inc De
전화
(650) 244-4990
주소
400 OYSTER POINT BLVD, SAN FRANCISCO
TTNP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
3.84 | 3.51M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.35 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.33 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.60 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.24 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.43 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
타이탄 파마슈티컬스 Stock (TTNP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-26 | 개시 | Maxim Group | Buy |
| 2017-11-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
타이탄 파마슈티컬스 주식(TTNP)의 최신 뉴스
Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan
KalVista Strengthens Team with Strategic 87,000-Share Option Grant Package - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Major Cancer Breakthrough: Zentalis Reveals New Azenosertib Data Across Multiple Tumor Types - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Major Shake-up Looms: Activist Investor Challenges Atea Pharmaceuticals Board Control - Stock Titan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan
NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan
Armata CEO Dr. Deborah Birx Takes Center Stage at Major Bacteriophage Summit - Stock Titan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan
ESSA Pharma's Pivotal Shareholder Meeting: 7 Directors Confirmed Amid Company Transition - Stock Titan
How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan
Will Amphastar Reveal New Strategic Insights at Upcoming Barclays Healthcare Conference? - Stock Titan
Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan
Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan
Tenaya's $52.5M Offering: What Does This Massive 75M Share Dilution Mean for TNYA Investors? - Stock Titan
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
Gene Therapy Pioneer Rocket Pharmaceuticals Secures Funding Through 2026 Despite Wider Losses - Stock Titan
Can This New Estée Lauder Partnership Transform How Your Skin Ages? - Stock Titan
Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan
How Nuvectis Pharma Cut Losses by $3.3M While Pushing Forward Two Cancer Drug Candidates - Stock Titan
Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - Stock Titan
Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan
Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan
Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan
Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - Stock Titan
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan
Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan
Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan
Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - Stock Titan
타이탄 파마슈티컬스 (TTNP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):